About Viridian Bio
Viridian Bio is a Healthcare company based in Philadelphia (United States) founded in 2019 by Tomas Kiselak and Peter Harwin, and was acquired by MiRagen in October 2020. Providing aid in translating basic science research into products. Viridian Bio has raised $29 million across 2 funding rounds from investors including MiRagen. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Viridian Bio was established in 2019 in Philadelphia, United States, within the biotechnology sector. A platform is utilized to validate scientific findings and identify differentiated molecules addressing high unmet medical needs. Operations focus on aiding the transition of basic research into viable products, with new companies formed to handle commercialization based on confirmed hypotheses.
- Headquarters Philadelphia, United States
- Founders Tomas Kiselak, Peter Harwin
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website viridianbio.com
- Social LinkedIn
- Acquired by MiRagen (Oct 2020)
Funding Insights of Viridian Bio
Viridian Bio has successfully raised a total of $29M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $27 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29M
- Total Rounds 2
- Last Round Series A — $27M
- First Round $2M
(May 2020)
All 2 funding rounds of Viridian Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $27M | Series A | – | – | – |
| May 2020 | $2M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Viridian Bio
Viridian Bio has secured backing from 1 investor. Prominent investors backing the company include MiRagen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
MicroRNA-based therapeutics are developed for treating multiple diseases. | 2007 | miragen.com | Boulder, United States |
Investor details for Viridian Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Viridian Bio
2 people are tracked at Viridian Bio (2 in leadership).
| Name | Role | Group |
|---|---|---|
Tomas Kiselak | Founder | Leadership |
Peter Harwin | Founder | Leadership |
Complete people profiles for Viridian Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Viridian Bio
4 dated milestones of Viridian Bio across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Viridian Bio is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series A, of $27.0M.
- Exit Acquired by MiRagen.
Competitors of Viridian Bio
Viridian Bio has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of Viridian Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Viridian Bio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Viridian Bio
Viridian Bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Viridian Bio is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Viridian Bio is a funded company, having raised a total of $29M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on May 2020.
Viridian Bio was established in 2019 in Philadelphia, United States, within the biotechnology sector. A platform is utilized to validate scientific findings and identify differentiated molecules addressing high unmet medical needs. Operations focus on aiding the transition of basic research into viable products, with new companies formed to handle commercialization based on confirmed hypotheses.
Viridian Bio's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.
Viridian Bio has 1 investor. Key investors include MiRagen.
Yes. Viridian Bio was acquired by MiRagen in October 2020.